HIV-1 infection – Page 3 – Communicable Diseases Research

COVID-19 and HIV-Associated Immune Reconstitution Inflammatory Syndrome: Emergence of Pathogen-Specific Immune Responses Adding Fuel to the Fire

Immunology

Published on 2021-03-242022-11-01
Journal: Frontiers in Immunology [Category] COVID-19, SARS,

CCR5Delta32 deletion as a protective factor in Czech first-wave COVID-19 subjects

체코 1세대 COVID-19 피험자에서 보호 인자로서의 CCR5Delta32 결실

Article

Published on 2021-03-172022-09-11
Journal: Physiological research [Category] 변종,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Asymptomatic candidate carrier carriers cause CCR5 cells Chemokine receptor coronavirus coronavirus disease Course COVID-19 Deletion ENCODE first-wave Frequency Genetic genetic mutation genetic susceptibility genotyped globe highest HIV-1 HIV-1 infection homozygous I/D polymorphism Infection inter-individual lowest middle Mutation Patient predict PROTECT Protective protective factor Protein receptor SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severity Significant Spread subject subjects survivor symptomatic virus
[DOI] 10.33549/physiolres.934647 PMC 바로가기 [Article Type] Article

Adaptation of advanced clinical virology assays from HIV-1 to SARS-CoV-2

HIV-1에서 SARS-CoV-2로의 고급 임상 바이러스 분석 적응

Review

Published on 2021-01-012022-09-11
Journal: Current opinion in HIV and AIDS [Category] 치료기술,

[키워드] adaptation analyses antiviral therapeutics applied approaches Blood conserved COVID COVID-19 pandemic disease severity Evidence genetic diversity Genetic variation HIV-1 HIV-1 infection IMPROVE infected individual infected individuals knowledge molecular Neutralizing antibodies nucleic acid outcome pandemic Pathogenesis Phylogenetic analysis plasma Precision Prognosis recent reverse transcriptase reverse transcriptase PCR RT-PCR SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2 sequence SARS-CoV-2 sequences SARS-CoV-2 sequencing sensitive sequence Sequencing shown small molecule small molecule inhibitor Small molecule inhibitors Stage susceptibility therapy Vaccines Viral viral replication Viral RNA viral RNA quantification
[DOI] 10.1097/COH.0000000000000656 PMC 바로가기 [Article Type] Review

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein

HIV 서브타입 C DNA 및 MF59-보강 서브타입 C 엔벨로프 단백질의 안전성 및 면역원성을 평가하기 위한 1상 인간 면역결핍 바이러스(HIV) 백신 시험

Articles and Commentaries

Published on 2021-01-012022-09-06
Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease,

[키워드] adjuvant administration advancement African Antibody Response antibody response rate Biojector boost CD4 cellular clinical Department DNA DNA prime/protein boost Efficacy elicited enrolled envelope envelope protein evaluate followed by glycoprotein greater healthy HIV HIV vaccine HIV-1 HIV-1 infection Human Human immunodeficiency virus Humoral response immunogenicity injected injection intramuscularly network partnership Phase 1 Placebo priming Protein Randomized regimen Registration registry response rate Result risk Safe Safety significantly significantly higher South South Africa subtype subtype C T-cell Response T-cell responses Trial vaccination Vaccine
[DOI] 10.1093/cid/ciz1239 PMC 바로가기 [Article Type] Articles and Commentaries

Identification and Tracking of Antiviral Drug Combinations

Article

Published on 2020-10-182022-10-28
Journal: Viruses [Category] COVID-19, MERS, SARS,

[키워드] A549 cells acute respiratory syndrome addition Antiviral antiviral drug antiviral drug combinations antivirals broad-spectrum antivirals calu-3 cells cells Combination convalescent serum coronavirus cycloheximide demonstrated developmental drug Efficacy EIDD-2801 epithelial HCV hepatitis C virus HIV-1 HIV-1 infection homoharringtonine Human immunodeficiency virus human lung identification identify in vitro Infection infections monensin monotherapy neutralizing antibody Prevent purified reduced Remdesivir resource SARS-CoV-2 synergistic synergy therapy Toxicity treat treatment for HIV viral strain virus
[DOI] 10.3390/v12101178 PMC 바로가기 [Article Type] Article

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

HIV에 감염되지 않은 건강한 성인을 대상으로 한 두 가지 이종 HIV 백신 요법의 안전성 및 면역원성(TRAVERSE): 무작위 배정, 병렬 그룹, 위약 대조, 이중 맹검, 1/2a상 연구

Articles

Published on 2020-09-302022-09-06
Journal: The Lancet. HIV [Category] Communicable Disease,

[키워드] 95% CI Ad26 Adenovirus Administered advancement adverse event adverse events aligned All participant All participants Analysis Antigen antigens applied assigned binding antibodies binding antibody blood sample breadth CD4+ T-cell clade collected computer-generated Defense Deltoid muscle Department diagnosed dose double-blind Efficacy elicit Eligible participants ELISpot responses enrolled finding first vaccination foundation funding group groups healthy Heterologous HIV HIV infection HIV vaccine HIV-1 infection HIV-uninfected IFNγ ELISPOT response IFNγ ELISPOT responses IgG immune response immune responses Immunity immunogenicity injection Intramuscular injection investigator investigators Jackson janssen Laboratory Local magnitude median medical history Medicine Melinda Gate Melinda Gates Military Medicine mononuclear cell mononuclear cells opinion Other parallel-group participant PBMC PBMCs per protocol per-protocol Peripheral blood Peripheral blood mononuclear cells Physical examination Placebo placebo group placebo-controlled placebos prevention randomisation randomised Randomly randomly permuted block randomly permuted blocks regimen regimens Registered repeated risk Safe Safety second vaccination Sponsor stratified subgroups systemic reactogenicity T-cell Response tested tetravalent the placebo group titre titres Tolerability treatment allocation Trial trivalent USA vaccination vaccination schedule Vaccinations Vaccine vaccine group vectored vaccine vital sign was done with HIV
[DOI] 10.1016/S2352-3018(20)30229-0 PMC 바로가기 [Article Type] Articles

Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial

HIV 감염, 항레트로바이러스 경험이 없는 성인에서 표준 용량 대비 저용량 테노포비르 디소프록실 푸마르산염 및 에파비렌즈의 효능 및 안전성: 다기관, 무작위, 비열등성 시험

Article

Published on 2020-05-042022-09-06
Journal: Emerging Microbes & Infections [Category] Communicable Disease,

[키워드] 95% CI adverse event adverse events antiretroviral ARV assigned change comparable dose drug efavirenz Efficacy evaluate filtration rate fumarate glomerular filtration rate HIV HIV-1 HIV-1 infection infected patients initial intention-to-treat analysis lamivudine low dose lower dose lower toxicity multicentre non-inferiority non-inferiority margin non-inferiority trial occurred Open-label participant primary endpoint proportion Randomized Randomly receive receiving reduced regimen safety profile Standard dose Support tenofovir tenofovir disoproxil tenofovir disoproxil fumarate therapy Toxicity Treatment treatment difference Trial two groups
[DOI] 10.1080/22221751.2020.1752609 PMC 바로가기 [Article Type] Article

HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome

Review

Published on 2015-09-302024-09-02
Journal: Seminars in immunopathology [Category] 대상포진,

[키워드] Drug therapy-complications HIV-1 infection immune reconstitution inflammatory syndrome Tuberculosis
[DOI] 10.1007/s00281-015-0532-2 PMC 바로가기 [Article Type] Review

PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged ≥3 months to <6 years

Research Article

Published on 2015-06-102024-09-02
Journal: Journal of the International AIDS Society [Category] 대상포진,

[키워드] Antiretroviral therapy atazanavir powder Child HIV-1 infection Infant paediatric formulations ritonavir liquid
[DOI] 10.7448/IAS.18.1.19467 PMC 바로가기 [Article Type] Research Article

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial

HIV-1에 감염된 건강한 성인에서 후보 결핵 백신 MVA85A의 안전성, 면역원성 및 효능: 무작위, 위약 대조, 2상 시험

Articles

Published on 2015-03-012022-09-06
Journal: The Lancet. Respiratory Medicine [Category] Communicable Disease,

[키워드] 1:1 95% CI absence active tuberculosis adverse event Antigen antigen 85A antigen 85A-specific T-cell response antiretroviral Antiretroviral therapy assigned assist baseline baseline CD4 block blocks booster Cape CD4 count CD4 counts Cell clinical defined detect detectable Developing disease double-blind effective Efficacy eligible Eligible participants enrolled enrolment European Evidence evidence of expressing finding first vaccination foundation funding gold greater Group allocation had no healthy HIV-1 HIV-1 infection immunogenic immunogenicity include increased risk Infection injection intradermal injections investigators isoniazid isoniazid prophylaxis Laboratory latent tuberculosis latent tuberculosis infection M tuberculosis Measures Melinda Gate Melinda Gates modified vaccinia virus MVA85A Mycobacterium tuberculosis nine no evidence of Nurses occurred outcome participant partnership peaked per-protocol analysis per-protocol population Phase 2 phase 2 trial Placebo placebo group placebo-controlled positive Potential Prophylaxis protocol QuantiFERON QuantiFERON-TB Gold In-Tube randomisation randomised Randomly receive receiving Registered reported Safe Safety safety analysis second vaccination secondary Secondary outcomes sequence Serious Adverse Event Serious Adverse Events significant increase South Africa stratified subset T-cell Response the placebo group therapy town Treatment Trial Tuberculosis tuberculosis disease tuberculosis vaccine undetectable vaccination Vaccine vaccine efficacy vaccine-induced immune response Viral Viral load Wellcome Trust were assessed
[DOI] 10.1016/S2213-2600(15)00037-5 PMC 바로가기 [Article Type] Articles